SCHEMBL648139

SCHEMBL648139

CCCCn1c(-c2ccccc2)nc(Cl)c1CN(Cc1cccc(C)c1)Cc1ccc2c(c1)OCCO2

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.54
PTGDR2 Q9Y5Y4 2/20 0.39
TP53 P04637 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP2D6 P10635 1/20 0.37
CYP2C8 P10632 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 1/20 0.36
F2R P25116 1/20 0.36
GBA1 P04062 1/20 0.36
TERT O14746 1/20 0.35
TSHR P16473 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652376 0.95 C5AR1 (0.58) C5AR1PTGDR2LMNASMN1; SMN2L3MBTL1
SCHEMBL1913081 0.93 C5AR1 (0.54) C5AR1PTGDR2LMNASMN1; SMN2L3MBTL1
SCHEMBL651035 0.93 C5AR1 (0.54) C5AR1PTGDR2LMNASMN1; SMN2L3MBTL1
SCHEMBL648614 0.93 C5AR1 (0.55) C5AR1PTGDR2TP53LMNASMN1; SMN2
SCHEMBL1912840 0.92 C5AR1 (0.63) C5AR1LMNASMN1; SMN2L3MBTL1F2R
SCHEMBL649928 0.92 C5AR1 (0.52) C5AR1PTGDR2LMNASMN1; SMN2L3MBTL1
SCHEMBL648693 0.91 C5AR1 (0.55) C5AR1PTGDR2TP53LMNASMN1; SMN2
SCHEMBL649257 0.90 C5AR1 (0.56) C5AR1PTGDR2LMNASMN1; SMN2L3MBTL1
SCHEMBL648111 0.90 C5AR1 (0.51) C5AR1PTGDR2LMNASMN1; SMN2L3MBTL1
SCHEMBL650515 0.90 C5AR1 (0.54) C5AR1PTGDR2LMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed